Loading...
•
Jun 30, 2021
Insulet Q2 2021 Earnings Report
Insulet reported a revenue increase of 16% year-over-year.
Key Takeaways
Insulet Corporation reported second quarter 2021 revenue of $263.2 million, up 16.3% compared to the prior year. Total Omnipod revenue increased by 19.9%, driven by growth in both U.S. and International markets. The company is reaffirming its revenue guidance range of 16% to 20% for the year ending December 31, 2021.
Second quarter 2021 revenue increased by 16.3% to $263.2 million.
Total Omnipod revenue grew by 19.9% to $242.1 million.
Gross margin increased to 69.4%, up 640 basis points.
Adjusted EBITDA reached $52.3 million, representing 19.9% of revenue.
Revenue by Segment
Forward Guidance
The Company expects revenue growth of 11% to 18% for the quarter ending September 30, 2021.
Positive Outlook
- Total Omnipod revenue growth of 17% to 23%
- U.S. Omnipod revenue growth of 23% to 28%
- International Omnipod revenue growth of 8% to 14%
Challenges Ahead
- Drug Delivery revenue decline of (40)% to (28)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...